Merck Healthcare KGaA

29 trials 5 recruiting Commercial sponsor Merged from 2 name variants

Filter these 29 trials by condition, phase, country and more.

Open in Search →

29 Registered trials

5 Recruiting

21 Completed trials

17 Countries active

15 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 5 Phase II: 6 Phase I/II: 4 Phase I: 5 Phase I (Other): 9

Oversight events:

5 temporary halts 1 urgent safety measure 1 corrective measure across 6 trials

View oversight register →

100%

21 of 21 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acute cutaneous lupus erythematosus 2 Systemic lupus erythematosus rash 2 Cutaneous lupus erythematosus 2 Subacute cutaneous lupus erythematosus 2 Chronic cutaneous lupus erythematosus 2 Metastatic gastric cancer 1 Ovarian epithelial cancer 1 Squamous cell carcinoma of head and neck 1 Ductal adenocarcinoma of pancreas 1 Infertility female 1 Non-small cell lung cancer metastatic 1 Soft tissue sarcoma 1

Top IMPs

ENPATORAN 3 PRECEMTABART TOCENTECAN 3 2-AMINO-6-FLUORO-N-(5-FLUORO-4-(1-METHYL-1H-IMIDAZOL-5-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE 2 AVELUMAB 2 ENPATORAN HEMIHYDRATE 2 TEPOTINIB 2 8-(1,3-DIMETHYLPYRAZOL-4-YL)-1-(3-FLUORO-5-METHOXYPYRIDIN-4-YL)-7-METHOXY-3-METHYLIMIDAZO[4,5-C]QUINOLIN-2-ONE 1 CEMIPLIMAB 1 CLADRIBINE 1 LENVATINIB 1 NIRAPARIB TOSILATE MONOHYDRATE 1 OSIMERTINIB 1

All trials — page 2

29 total

Study of tuvusertib (M1774) in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors Ended

2022-500287-35-00 Phase I (Other) 1 country
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended

2024-510872-18-00 Phase II 5 countries ENPATORAN
Study of Avelumab in combination with Lenvatinib for children with primary CNS tumors Ended

2024-512940-51-00 Phase I (Other) 2 countries AVELUMAB; LENVATINIB
Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended

2024-512005-87-00 Phase II 5 countries OSIMERTINIB; TEPOTINIB
Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplification Ended

2024-512003-39-00 Phase II 7 countries TEPOTINIB

Showing 25–29 of 29 trials

← All sponsors A–Z